This is an investigational study. Sorafenib is FDA approved for treatment of advanced renal cell cancer. Its use in this study, for this disease, is investigational. Carboplatin and paclitaxel are FDA approved and commercially available. Up to 42 patients will take part in this study. All will be enrolled at MD Anderson.